Peter A Cattini Selected Research

Placental Lactogen (Human Placental Lactogen)

1/2021	A potential role for insulin treatment during pregnancy in reducing postpartum psychological distress in maternal obesity: an administrative population health study.
11/2020	Obesity and regulation of human placental lactogen production in pregnancy.
10/2018	Chromosomal architecture and placental expression of the human growth hormone gene family are targeted by pre-pregnancy maternal obesity.
8/2013	CCAAT-enhancer-binding protein β (C/EBPβ) and downstream human placental growth hormone genes are targets for dysregulation in pregnancies complicated by maternal obesity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter A Cattini Research Topics

Disease

6	Obesity 01/2022 - 04/2002
6	Neoplasms (Cancer) 01/2019 - 10/2011
4	Maternal Obesity 01/2021 - 08/2013
4	Reperfusion Injury 09/2013 - 03/2002
3	Cardiotoxicity 01/2019 - 02/2017
3	Cardiomegaly (Heart Hypertrophy) 01/2007 - 01/2003
2	Insulin Resistance 10/2018 - 08/2013
2	Hypertrophy 08/2004 - 01/2003
2	Ischemia 03/2002 - 02/2002
1	Hyperphagia (Overeating) 03/2021
1	Gestational Diabetes (Gestational Diabetes Mellitus) 01/2021
1	Anhedonia 01/2021
1	Insulinoma 04/2019
1	Type 2 Diabetes Mellitus (MODY) 04/2019
1	Hyperglycemia 04/2019
1	Pituitary Neoplasms (Pituitary Adenoma) 09/2012
1	Hypoxia (Hypoxemia) 09/2012
1	Cardiovascular Diseases (Cardiovascular Disease) 07/2010
1	Infarction (Infarctions) 01/2007
1	Myocardial Ischemia (Ischemic Heart Diseases) 12/2004
1	Heart Failure 08/2004
1	Infections 04/2003
1	Carcinogenesis 01/2003
1	Fibrosis (Cirrhosis) 01/2003
1	Vascular Remodeling 01/2003
1	Mason-Type Diabetes 04/2002
1	Coronary Occlusion 03/2002
1	Myocardial Infarction 03/2002

Drug/Important Bio-Agent (IBA)

10	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 01/2019 - 02/2002
5	Insulin (Novolin)FDA Link 03/2021 - 04/2002
4	Placental Lactogen (Human Placental Lactogen)IBA 01/2021 - 08/2013
4	RNA (Ribonucleic Acid)IBA 11/2020 - 09/2012
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019 - 04/2013
3	Human Growth Hormone (Saizen)FDA LinkGeneric 10/2018 - 10/2011
2	Hormones (Hormone)IBA 01/2022 - 10/2018
2	Transcription Factors (Transcription Factor)IBA 11/2020 - 08/2013
2	Histones (Histone)IBA 01/2015 - 04/2003
2	Pharmaceutical PreparationsIBA 09/2013 - 04/2013
2	Protein Isoforms (Isoforms)IBA 01/2007 - 08/2004
1	Sucrose (Saccharose)IBA 01/2021
1	Tuberculin (PPD)IBA 01/2021
1	PalmitatesIBA 04/2019
1	Nonesterified Fatty Acids (NEFA)IBA 04/2019
1	Glucose (Dextrose)FDA LinkGeneric 04/2019
1	AntioxidantsIBA 10/2017
1	trichostatin A (A 300)IBA 01/2015
1	theasinensin AIBA 01/2015
1	Decitabine FDA Link 01/2015
1	ChromatinIBA 01/2015
1	Growth Hormone (Somatotropin)IBA 08/2013
1	A-factor (Streptomyces)IBA 08/2013
1	Small Interfering RNA (siRNA)IBA 08/2013
1	CCAAT-Enhancer-Binding ProteinsIBA 08/2013
1	AnthracyclinesIBA 04/2013
1	NucleotidesIBA 09/2012
1	Thyroid HormonesIBA 10/2011
1	Dexamethasone (Maxidex)FDA LinkGeneric 10/2011
1	NF-kappa B (NF-kB)IBA 07/2010
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2004
1	AngiotensinsIBA 08/2004
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 03/2002
1	Protein Kinase CIBA 03/2002
1	chelerythrineIBA 03/2002